Navigation Links
Celebrex may help prevent some non-melanoma skin cancers
Date:11/30/2010

BIRMINGHAM, Ala. New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.

The researchers, led by University of Alabama at Birmingham dermatologist and the study's lead author, Craig Elmets, M.D., evaluated the efficacy and safety of celecoxib as a chemo-preventive agent for actinic keratoses. The results were published online Nov. 30, 2010, in the Journal of the National Cancer Institute. It will appear in the print edition of the journal Dec. 15.

Cutaneous squamous cell carcinomas and basal cell carcinomas are the most common malignancies in the United States. More than 2 million people are diagnosed each year with non-melanoma skin cancer and instances of malignancies are increasing, especially in young people. The direct treatment of these has been estimated to exceed $1.4 billion annually.

Previous research data has suggested that cyclooxygenase 2 is involved in the development of non-melanoma skin cancers. In animal models, the cyclooxygenase 2 inhibitor celecoxib, better known by its brand name Celebrex, inhibits the development of ultraviolet-induced pre-malignant skin papillomas, which are thought to correspond to actinic keratoses, the pre-malignant precursor of non-melanoma skin cancers

Currently, celecoxib is used to relieve pain, tenderness, swelling and stiffness caused by osteoarthritis, rheumatoid arthritis and spinal arthritis. It also is can be used off-label to treat painful menstrual periods and pain from other causes and is used to reduce the number of polyps in the colon and rectum in patients with familial adenomatous polyposis. Celecoxib is in a class of NSAIDs called COX-2 inhibitors.

The double-blind, placebo-controlled trial looked at 240 subjects ages 37 to 87 years with 10 to 40 actinic keratoses at eight U.S. academic medical centers during an 11-month period.

At nine months after randomization, there was no difference in the incidence of new actinic keratoses developed between the placebo group and those receiving celecoxib, which was the primary endpoint of the study. However, compared with the placebo, celecoxib when looked at duing the 11-month visit was highly effective in preventing nonmelanoma skin cancers from developing in subjects who had large numbers of actinic keratoses.

"While celecoxib was not effective in preventing new actinic keratoses the study raises the possibility that the drug is effective in preventing cancer from developing from the precancerous actinic keratoses lesions," Elmets said.

Future studies are planned to establish if other NSAIDs have the same properties as Celebrex as skin-cancer chemopreventive agents. Topical NSAIDs also are being investigated to determine if they can be used to prevent skin cancers.


'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Celebrex Shows Potential in Preventing Some Skin Cancers: Study
2. Celebrex Appears Easier on Stomach for Arthritis Patients
3. Can Celebrex prevent cancer-causing colon polyps?
4. Celecoxib may be effective in preventing non-melanoma skin cancers
5. Light exercise may prevent osteoarthritis
6. Gene therapy prevents memory problems in mice with Alzheimers disease
7. Disease Prevention Could Save U.S. Billions of Dollars Annually
8. Missed opportunities: Most heart attack patients are not taking preventive medications
9. Few eligible young women choose to take HPV vaccine to prevent cervical cancer, study shows
10. New Drug, Pradaxa, May Prevent Second Stroke in Certain Heart Patients
11. Many Falls, and Resulting ER Visits, Can Be Prevented
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 28, 2016 , ... "Color Grading media can be time consuming but with ... media," said Christina Austin - CEO of Pixel Film Studios. , With the ... stylish color grades to their footage. A LUT is a Lookup Table that contains ...
(Date:5/28/2016)... , ... May 28, 2016 , ... In a part of the city where’s it’s ... new farm-to-table Kelowna restaurants is hoping to attract diners with a taste for ... Suites officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Two director-level ... as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes ... workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute ... for a sustainable product to aid in the rehabilitation process has steadily increased. Ekso ... of individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response ... many who are unaware of the plight of aphasia. In collaboration with the ... “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively unknown, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
(Date:5/25/2016)... 25, 2016 ReportsnReports.com adds ... report that provides an overview on therapeutic pipeline ... various stages, therapeutics assessment by drug target, mechanism ... molecule type, along with latest updates, and featured ... players involved in the therapeutic development for Chronic ...
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
Breaking Medicine Technology: